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Abstract
Polymorphisms in the T cell (or transmembrane) immunoglobulin and mucin
 ( ) gene, particularly in the mucin domain, have been associateddomain 1 TIM-1
with atopy and allergic diseases in mice and human. Genetic- and
antibody-mediated studies revealed that Tim-1 functions as a positive regulator
of Th2 responses, while certain antibodies to Tim-1 can exacerbate or reduce
allergic lung inflammation. Tim-1 can also positively regulate the function of B
cells, NKT cells, dendritic cells and mast cells. However, the precise molecular
mechanisms by which Tim-1 modulates immune cell function are currently
unknown. In this study, we have focused on defining Tim-1-mediated signaling
pathways that enhance mast cell activation through the high affinity IgE
receptor (FceRI). Using a Tim-1 mouse model lacking the mucin domain (Tim-1
), we show for the first time that the polymorphic Tim-1 mucin region is
dispensable for normal mast cell activation. We further show that Tim-4
cross-linking of Tim-1 enhances select signaling pathways downstream of
FceRI in mast cells, including mTOR-dependent signaling, leading to increased
cytokine production but without affecting degranulation.
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Introduction
T-cell immunoglobulin and mucin domain (TIM)-1 belongs to 
a family of type I transmembrane proteins with essential roles in 
immune regulation. Tim-1 has an N-terminal IgV domain, a mucin-
like domain with multiple potential sites for O-linked glycosylation, 
followed by a stalk domain with potential N-linked glycosylation 
sites, a transmembrane domain, and a short cytoplasmic tail. Tim-1 
was initially identified as a cellular receptor for hepatitis A virus 
(HAVCR1)1. The TIM-1 gene was positionally cloned from a locus 
on the same chromosome but distinct from the IL-4 gene cluster 
that is commonly associated with Th2-biased immune responses2. 
Polymorphisms in murine Tim-1 are associated with susceptibil-
ity to airway hyper-reactivity (AHR), a hallmark of asthma, and 
increased Th2 cytokine production2. Similarly, polymorphisms in 
human TIM-1 have been linked to atopic diseases including asthma, 
allergic rhinitis and atopic dermatitis3. The atopy connection is par-
ticularly intriguing since genetic variations in human TIM-1 modify 
susceptibility or resistance to allergy, but only in individuals sero-
positive for HAV4. These findings suggested that Tim-1 has a role in 
regulation of immune responses to atopic diseases.
Mechanistically, Tim-1 was shown to co-stimulate T effector cell 
proliferation, with preferential effects on Th2 cytokine production. 
Thus, the high affinity agonistic monoclonal antibody (mAb) 3B3 
was reported to inhibit the induction of respiratory tolerance in an 
AHR model5, and to enhance both T cell proliferation and cytokine 
production in vitro and in vivo5,6. Antibodies recognizing distinct 
epitopes of Tim-1 either enhanced or attenuated lung inflammation7. 
We further showed that ectopic expression of Tim-1 in T cells stim-
ulated in vitro under “neutral” conditions promoted generation of 
more IL-4- rather than INF-γ production6. Tim-1 can also enhance 
NFAT/AP-1-dependent transcription in T cells activated by TCR 
crosslinking, suggesting that Tim-1 functions as a co-stimulatory 
molecule for T cell activation8. Similarly, co-stimulatory func-
tion of Tim-1 was also observed after interaction of Tim-1 with its 
ligand Tim-4, which is primarily expressed on APCs9,10.
Regarding signaling pathways coupled to Tim-1, we showed that 
tyrosine 276 in the cytoplasmic tail of Tim-1 could be phospho-
rylated in an Lck-dependent manner. This allows for recruitment 
of the p85α and β subunits of the PI3K, leading to activation of 
the downstream kinase Akt and subsequent activation of the tran-
scription factors NFAT and AP-18. Administration of the agonistic 
Tim-1 antibody 3B3 induces expression of early activation markers 
CD69 and CD25 as well as IL-2 production8. Other groups have 
demonstrated that ligation of Tim-1 by Tim-4 can activate the ERK/
MAPK pathway and enhance T cell survival by up-regulating the 
anti-apoptotic protein BcL-xL9. Additional studies revealed that 
Tim-1 could co-cap with CD3 on human T cells11. Tim-1 ligation 
on T cells has also been reported to induce tyrosine phosphorylation 
of the linker for activation of T cells (LAT) and the TCR-proximal 
Syk family tyrosine kinase Zap709. Taken together, these findings 
suggested that Tim-1 may interact with proximal TCR signaling 
complexes.
In addition to T cells, Tim-1 also has regulatory functions on other 
non-immune and immune cell types. Tim-1, also known as kidney 
injury molecule (KIM)-1, is upregulated on renal proximal tubules 
and shed upon acute renal failure12. Apoptotic cell recognition by 
Tim-1, specifically on natural killer T (NKT) cells, may induce AHR 
in response to respiratory syncytial virus- or ozone-induced experi-
mental asthma13. Tim-1 has recently been shown to be expressed by 
IL10-secreting regulatory B cells and Tim-1 signaling is required 
for the induction and maintenance of these cells14,15. Specifically, the 
Tim-1 mucin domain is required for IL-10 production in response to 
phosphatidylserine (PS) binding and allograft tolerance14,15. Tim-1 
is also constitutively expressed on bone marrow-derived (BMMC) 
and peritoneal (PMC) mast cells. Cross-linking of Tim-1 by Tim-4 
enhanced IgE plus antigen-stimulated (IgE/Ag) production of 
Th2 type cytokines16. However, the mechanisms by which Tim-1 
modulates mast cell functional responses are currently unknown.
Mast cells are among the first responders of immune responses 
against pathogens and allergens. They have the capacity to secrete a 
multitude of pro- and anti-inflammatory factors that regulate aller-
gic inflammation, pathogen defense, and anti-tumor immunity17. 
Given the genetic and functional connection of Tim-1 to allergy 
and hypersensitivity and the sentinel role of mast cells in atopy, it 
is important to determine how Tim-1 signaling contributes to the 
high affinity Fc receptor for IgE (FcεRI)-mediated mast cell activa-
tion. Here we demonstrate that Tim-1 promotes NF-κB and NFAT/
AP1 transcriptional activation, leading to enhanced IL-6 promoter 
activation and cytokine production in IgE/Ag-stimulated mast 
cells. Using BMMCs generated from a mouse strain lacking the 
Tim-1 mucin domain (Tim1Δmucin), we show that this co-stimulatory 
effect is independent of the Tim-1 mucin domain. Finally, we show 
that Tim-1, in contrast with Tim-3, acts more distal to FcεRI to 
enhance S6 activation, without affecting proximal FcεRI signaling. 
Overall, our findings provide a mechanistic explanation for the co-
stimulatory effects of Tim-1 signaling on FcεRI-mediated mast cell 
activation.
Methods
Antibodies and reagents
Monoclonal anti-dinitrophenyl (DNP), IgE isotype, clone 
SPE-7 (Cat No. D8406), DNP32-HSA (Cat No. A6661), anti-
FLAG M2 antibody (Cat No. F1804), cyclosporine A (Cat 
No. C1832), and 4-Nitrophenyl N-acetyl-β-D-glucosaminide 
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(pNAG) (Cat No. N9376) were purchased from Sigma-Aldrich (St. 
Louis, MO). DNP5-BSA (Cat No. D5050) was from Biosearch Tech-
nologies (Petaluma, CA). Monoclonal antibodies to murine Tim-1 
(3B3, RMT1-10, 5G5, 5F12) and purified Tim4-Fc (the latter 
consists of the IgV and mucin domains of murine Tim-4 fused to 
the constant region of hIgG1) were obtained from Vijay Kuchroo 
(Harvard Medical School). Human IgG as isotype control for 
Tim4-Fc was purchased from Jackson ImmunoResearch Labo-
ratories (Cat No. 009-000-003, West Grove, PA). Monoclonal 
antibodies to BALB/c Tim-1 (1H9, 3A2, 4A2, 4B2, 4G8, 5D1) 
were originally developed at Biogen and were obtained under 
an MTA with CoStim Pharmaceuticals (Cambridge, MA). Puri-
fied rat IgG2a as isotype control for Tim-1 antibodies was pur-
chased from eBioscience (Cat No. 14-4321-85, San Diego, CA). 
Phospho-specific antibody to ERK (T202/Y204) was from BD 
Biosciences (20 μl per test), (Cat No. 612566, San Jose, CA). 
Phospho-specific antibodies to Syk (Y519/520) (1:400, Cat No. 
2710), and S6 (S235/236), (1:150, Cat No. 4851) were obtained 
from Cell Signaling Technology (Danvers, MA). Anti-mouse 
Fc block (2.4G2) was purchased from BD Biosciences (Cat No. 
553141, San Jose, CA). IL-6 luciferase reporter constructs were 
obtained from Sarah Gaffen (University of Pittsburgh), originally 
from Oliver Eickelberg (Helmholtz Zentrum Munchen).
Mice
All studies were performed in accordance with University of 
Pittsburgh Institutional Animal Care and Use Committee proce-
dures. Specifically, mice were housed four males or five females 
per polycarbonate cage in a 12-hour light/dark cycle. Food and 
water were provided ad libitum. Cages and bedding were changed 
every seven days. Mutant mice lacking Tim-1 mucin domain 
(Tim-1Δmucin) were obtained from David Rothstein (University 
of Pittsburgh), and were originally from Vijay Kuchroo (Har-
vard Medical School). Age-and sex-matched wild-type C57BL/6 
were purchased from the Jackson Laboratory (Bar Harbor, ME) as 
control.
BMMC and mast cell line culture
Bone marrow cells from C57BL/6 Tim-1 wild-type (WT) and 
mutant (Tim-1Δmucin) were generated as described previously18. 
MC/9 mast cells were cultured in DMEM supplemented with 10% 
BGS, 2-ME, Pen/Strep with Glutamine, and 10% IL3-conditioned 
media.
BMMC stimulation, cytokine secretion, and phospho-flow 
cytometry
BMMCs (1 × 105 or 1 × 106 cells for cytokine measurement and 
3 × 105 cells for phospho-flow) were sensitized overnight with 
1 μg/ml IgE without IL-3 conditioned media. Cells were stimulated 
with DNP32-HSA or DNP5-BSA. Six or twenty-four hours post 
stimulation, supernatants were collected and assayed for murine 
IL-6 and TNF-α by ELISA (BioLegend). For phospho-flow stain-
ing, stimulated cells were fixed in 1.5% paraformaldehyde for ten 
minutes at room temperature and permeablized with ice cold metha-
nol for thirty minutes. Incubation with phospho-specific antibodies 
were performed per manufacturer’s instructions. Flow acquisition 
was performed on Fortessa or LSRII (BD Biosciences), and data 
were analyzed using FlowJo software version 8.7 (Tree Star).
Measurement of beta-hexosaminidase release
BMMCs (2.5 × 105 cells) were sensitized and subsequently stim-
ulated for thirty minutes in Tyrode’s buffer (135mM NaCl, 5mM 
KCl, 5.6mM glucose, 1.8mM CaCl2, 1mM MgCl2, 20mM HEPES, 
and 0.5mg/ml BSA). Supernatants (stimulated release) were col-
lected and cells were lysed (content) with 0.5% Triton-X100 in 
PBS for fifteen minutes on ice. Content and stimulated release 
fractions were incubated with 1mM pNAG substrate for 1 hour at 
37°C. Carbonate buffer (0.1M, pH 9.0) was added to stop reaction 
and absorbance was obtained at 405nm on a plate reader (BioTek 
ELx808). Percentage of beta-hexosaminidase release was calcu-
lated as (releasestimulated/contenttotal) × 100.
Mast cell degranulation assay by Annexin V-based flow 
cytometry
Degranulation was measured as described previously18,38. Briefly, 
BMMCs were loaded with 0.1μM of Lysotracker Deep Red 
(Invitrogen) for thirty minutes at 37°C prior to sensitization with 
0.5 μg/ml IgE for 1 hour. Ninety minutes after antigen cross-linking 
by DNP32-HSA, cells were collected and stained with Annexin V 
(BioLegend). %degranulation was determined as percentage of 
BMMCs that is AnnexinV+Lysotrackerlo. Flow acquisition was 
performed on Fortessa or LSRII (BD Biosciences), and data were 
analyzed using FlowJo software version 8.7 (Tree Star).
Transcriptional reporter luciferase assays
MC/9 mast cells (15 × 106) were transfected with 15 μg of IL6-luc, 
NF-κB-luc, or NFAT/AP1-luc with 5 μg of pCDEF3 (empty vector), 
FLAG-tagged Tim-1 full length (FL), Tim-1 cytoplasmic dele-
tion (Δcyto), or Tim-1 tyrosine mutant (Y276F). Electropora-
tion was performed at 290V, 950 μF using a Gene Pulser II 
apparatus (Bio-Rad). Cells were collected twenty-four hours 
post-transfection and stimulated with 0.5 μg/ml IgE and 30 ng/ml 
or 100 ng/ml of DNP32-HSA as antigen for six hours. Luciferase 
assays were performed as previously described39.
Statistical analysis
All statistical analyses was performed using Prism version 6.0 
(GraphPad Software). Paired, unpaired, two-tailed Student’s 
t-test, one-way and two-way ANOVA with multiple compari-
son were used for data analysis and calculation of p values, as 
appropriate.
Results
Dataset 1. Raw data for Figures 1–5 in ‘Mast cell activation is 
enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies’
http://dx.doi.org/10.5256/f1000research.8132.d114870 
Tim1-Tim4 interaction enhances mast cell cytokine 
production without affecting degranulation
Mast cells constitutively express surface Tim-1 and Tim-3, but 
not Tim-2 or Tim-416. Tim-1 cross-linking by Tim4-Fc was shown 
to enhance cytokine production in a dose-dependent manner 
without affecting degranulation16. We first confirmed that Tim4-Fc 
could bind to our cultures of bone marrow derived mast cells 
(BMMC) from C57BL/6 mice (Figure 1A). We observed similar 
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Figure 1. Tim4-Fc enhances IgE/Ag-mediated mast cell cytokine production at high but not low antigen valency stimulation without 
affecting degranulation. C57BL/6 BMMCs was incubated with 0.5 μg of Tim4-Fc or human IgG (iso) on ice for 20 minutes followed by flow 
cytometry analysis (A). BMMCs were sensitized overnight with 1 μg/ml of IgE and stimulated with 50 ng/ml of DNP32-HSA, alone or with 5 μg/ml 
of Tim4-Fc or isotype control Fc (“iso”) for six hours prior to IL-6 measurement by ELISA (B). BMMCs were sensitized with IgE and stimulated 
with DNP32-HSA in the presence of increasing amount of Tim4-Fc (0.1–50 μg/ml) for thirty minutes prior to degranulation measurement by 
means of beta-hexosaminidase release (C). Cells were loaded with Lysotracker Deep Red, sensitized with IgE, and stimulated with antigen 
plus isotype control or Tim4-Fc for ninety minutes prior to Annexin V staining and flow cytometry analysis (D). BMMCs were sensitized with 
IgE and stimulated with DNP32-HSA (E) or DNP5-HSA (F) alone or in conjunction with indicated amount of control Fc (“iso”) or Tim4-Fc for 
six hours. Anti-mouse Fc blocking Ab (2.4G2) was added as indicated for ten minutes prior to antigen and antibody stimulation. IL-6 cytokine 
production was determined by ELISA. Results are representative of three independent experiments with duplicates in each (B, E, F), average 
of four experiments (C), and at least three experiments (D). *p<0.05.
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effects of Tim4-mediated IL-6 production in IgE/Ag-stimulated 
BMMCs (Figure 1B). In addition, we quantified the degranula-
tion response by measuring beta-hexosaminidase release as well as 
with a flow cytometry-based assay that tracks both Annexin V 
binding to exposed PS and loss of Lysotracker staining, due to 
granule release (AnnexinV+Lysotrackerlo). The latter method 
has the advantage of a high signal-to-noise ratio, and as such has 
been a robust assay for evaluating IgE/Ag-stimulated mast cell 
degranulation18. Thus, we showed that varying the concentration 
of Tim-4, along with suboptimal antigen concentration to observe 
potential co-stimulation, did not have an effect on the immediate 
degranulation response (Figure 1C–D). These results suggest that 
Tim-1 ligation by Tim-4 can exert differential effects on the imme-
diate degranulation response, vs. late-phase cytokine production.
Antigen valency and concentration have been shown to control the 
outcomes of FcεRI engagement in not just quantitative, but also qual-
itative, fashions19. Specifically, low antigen concentration or valency 
will activate only positive FcεRI signaling pathways, while high 
antigen valency or concentration will preferentially engage negative 
signaling components downstream of FcεRI. This is due to activity 
of the Src family kinase Lyn as a positive and/or negative regulator 
of FcεRI signaling at low or high antigen valency, respectively19. 
We stimulated BMMCs with low (DNP5-BSA) or high (DNP32-HSA) 
potency antigens in the presence of Tim4-Fc or isotype control and 
assessed whether Tim-1 ligation could contribute to receptor sign-
aling intensity. Thus, at high antigen valency, which also activates 
negative feedback of antigen receptor signaling, Tim-4 was able 
to maintain high IL-6 production but not at low antigen valency 
that induces robust antigen receptor signaling (Figure 1E–F). Spe-
cifically, increasing the amount of Tim-4 further promoted cytokine 
secretion under high valency antigen stimulation, i.e. under con-
ditions where the negative signaling loop is triggered. To exclude 
the possibility that Fcγ receptor binding may interfere with 
Tim1-Tim4 interaction, we compared IL-6 release by BMMCs, 
with or without addition of Fc blocking antibody, and found no dif-
ferences, at least at the concentration of Tim4-Fc used throughout 
this study (5 μg/ml). These findings indicate that Tim-1 ligation 
can modulate the intensity of the antigen-induced positive FcεRI 
signaling pathways and may be able to bypass the negative feed-
back signaling loop controlled by Lyn.
Tim-1 antibodies do not have significant effects on IgE/ 
Ag-mediated mast cell activation
Several antibodies against Tim-1 have been tested and showed 
no effects on either IgE/Ag-induced mast cell degranulation or 
cytokine production16. Of significance are the mAbs 3B3 and 
RMT1-10, which have been termed “agonistic” and “antagonistic” 
antibodies, respectively, due to their ability to enhance or inhibit 
effector T cell activation20. Similarly, we did not observe any dose-
dependent effects of 3B3, RMT1-10 or the IgV domain-binding 
mAb 5F12 on levels of IL-6 and TNF-α secreted by IgE-sensitized 
and Ag-stimulated BMMCs (Figure 2A–D). We examined several 
other antibodies, generated against the BALB/c allele of Tim-1, 
which were shown to either exacerbate or ameliorate Th2-depend-
ent OVA-induced lung inflammation in mice7. Specifically, mAbs 
1H8 and 3A2 bind to distinct epitopes near an N-linked glycosyla-
tion site in the stalk region and have agonistic and antagonistic 
activity, respectively. The mAb 4A2 binds to the IgV domain of Tim-
1 and reduces lung inflammation and pathology7. However, aside 
from 4G8, we did not detect significant binding of these antibodies 
to BALB/c Tim-1. While 4G8 recognized surface Tim-1, it did not 
alter Ag-mediated cytokine production in mast cells (Figure 2E). 
Even though these antibodies were raised against the BALB/c 
allele of Tim-1, we also observed binding of 4G8 to C57BL/6 
Tim-1 (Figure 2F). Again, there was no detectable increase in IL-6 
production when these antibodies were used in co-stimulation 
with FcεRI crosslinking by IgE/Ag, on BMMC derived from 
C57BL/6 mice (Figure 2F). 
Tim-1 cytoplasmic tyrosine is required for enhancement of 
transcriptional activation
We previously demonstrated that transient expression of Tim-1 
co-stimulated TCR/CD28-mediated transcriptional activation of 
IL-4 and IFN-γ production and NF-AT/AP1-dependent transcrip-
tion. This co-stimulatory activity was dependent on tyrosine 276 in 
the Tim-1 cytoplasmic tail6. Similarly, ectopic expression of an 
N-terminal FLAG-tagged Tim-1 on MC/9 mast cells was able 
to enhance IgE/Ag-stimulated NF-κB transcriptional activation 
(Figure 3A). This enhancement was abrogated when the cytoplas-
mic tail of Tim-1 was deleted or when a tyrosine-phenylalanine 
mutant (Y276F) was used (Figure 3A). Polymorphisms in Tim-1 
have been associated with differential responses to OVA-induced 
allergic asthma2. We found that both isoforms of Tim-1 (BL/6 and 
BALB/c) could significantly enhance activation of an NF-κB tran-
scriptional reporter to a comparable extent (Figure 3B). Consistent 
with findings in T cells and effects on mast cell cytokine production, 
transient expression of Tim-1 also up-regulated NF-AT/AP1 and 
IL-6 promoter activation, in a tyrosine phosphorylation-dependent 
manner (Figure 3C–D). Furthermore, using IL-6 promoter deletion 
constructs, we showed that Tim-1 mediated enhancement of tran-
scriptional activation and subsequent production of IL-6 through 
activation of NF-κB andAP-1 transcription factors (Figure 3E). 
Unlike Tim-4 crosslinking of Tim-1, addition of anti-FLAG anti-
body could not further promote reporter activity, suggesting either 
that Tim-1 may have other ligands on MC/9 mast cells or that Tim-1 
can homo-dimerize after ectopic expression, via its heavily glyco-
sylated mucin domain, leading to downstream signaling.
Tim-1 mucin domain is not required for Tim4-mediated 
enhancement of mast cell cytokine production
Our findings thus far suggest that the Tim1-Tim4 interaction aug-
ments FcεRI signaling itself, rather than acting through a parallel 
pathway, since Tim-4 treatment alone does not induce any detect-
able cytokine production or degranulation. While the Tim1-Tim4 
interaction has been attributed primarily to the IgV domain, Tim-
4 has also been proposed to bind to the Tim-1 mucin domain10. 
Intriguingly, the genetic linkage of Tim-1 to allergies and asthma 
is associated with polymorphisms in the mucin domain. Using a 
mutant mouse lacking only the Tim-1 mucin domain (Tim-1Δmucin)21, 
we determined whether the Tim-1 mucin domain is necessary to 
relay the co-stimulatory effects of Tim-4 binding. We noted no obvi-
ous defects in mast cell development or maturation, when BMMC 
were generated from Tim-1Δmucin bone marrow. Thus, WT and 
Tim-1Δmucin BMMCs expressed comparable levels of surface Tim-1, 
based on staining with IgV-binding Tim-1 antibodies (Figure 4A). 
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Figure 2. Tim-1 antibodies did not significantly alter IgE/Ag-mediated mast cell cytokine production compared to ligation by Tim4-Fc. 
BL/6 or BALB/c BMMCs (1 × 106) as indicated were sensitized with IgE overnight and stimulated with DNP32-HSA in the presence of isotype 
control or monoclonal antibodies against Tim-1 3B3 (A–B), RMT1-10 (C–D), 3A2, 4A2, 4B2, 4G8, 1H9 (E) for six hours. The indicated 
antibodies were incubated with BALB/c BMMCs for 30 minutes on ice followed by anti-rat IgG-Alexa-647 secondary antibody, prior to flow 
cytometry analysis (E). Culture supernatants were analyzed for IL-6 and TNF-α by ELISA. BL/6 BMMCs were incubated with 4G8, 4A2 
and 5D1 antibodies followed by anti-rat IgG-Alexa 647 secondary antibody prior to flow cytometry analysis (F). BL/6 BMMCs sensitized 
with IgE overnight and stimulated with DNP32-HSA together with either isotype control or the indicated antibodies for six hours prior to IL-6 
measurement by ELISA (F). Results are representative of three (A–D) and two (E–F) independent experiments performed in duplicates.
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Figure 3. Tim1-mediated enhancement of transcriptional activation is dependent on a tyrosine on its cytoplasmic tail. MC/9 mouse 
mast cells were transfected with empty vector (pCDEF3), BL/6 or BALB/c Tim-1 (full length (FL)), BL/6 Tim-1 lacking the cytoplasmic region 
(Δcyto) or full length Tim-1 (BL/6) with tyrosine to phenylalanine mutated at tyrosine 276 (Y276). Transfected cells were stimulated with 
0.5 μg/ml IgE plus either 30 ng/ml or 100 ng/ml DNP32-HSA, with or without addition of anti-FLAG antibody for six hours. MC/9 mast cells were 
co-transfected NF-κB (A–B), NFAT/AP1 (C), and IL-6 (D) luciferase reporters. MC/9 mast cells were transfected with full length BL/6 Tim-1 
along with indicated IL-6 luciferase reporters and stimulated as described (E). Results are representative of three independent experiments 
performed in triplicate. *p<0.05, **p<0.005, ****p<0.00005.
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Figure 4. Tim-1 mucin domain is not required for Tim4-mediated enhancement of cytokine production in IgE/Ag-stimulated Tim-1Δmucin 
BMMCs. Tim-1 surface expression and maturity of WT and Tim-1Δmucin BMMCs were determined by FcεRI and c-kit staining (A). WT and 
Tim-1Δmucin BMMCs were sensitized overnight with IgE and stimulated with 10 ng/ml, 50 ng/ml, 100 ng/ml DNP32-HSA, and 5 μg/ml Tim4-Fc. 
Mast cell degranulation was measured by Annexin V and Lysotracker staining (B–C). Results are average of three (B) and two 
(C) independent experiments. Culture supernatants were collected and analyzed for IL-6 by ELISA (D). Using six separate batches of 
BMMCs. WT and Tim-1Δmucin BMMCs were stimulated with indicated amount of antigen with either 5 μg/ml isotype control Fc (iso) or Tim4-Fc 
for six hours (E–H). Results are comparison between WT and Tim-1Δmucin BMMCs from six independent experiments using six separate batches 
of BMMCs. *p<0.05.
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Tim-1Δmucin BMMCs exhibited a similar extent of degranulation in 
response to antigen stimulation, compared to WT BMMCs, which 
was not altered by Tim-1 ligation (Figure 4B–C). Next, we examined 
the ability of Tim-1Δmucin BMMCs to secrete cytokines in response 
to IgE/Ag. Tim-1Δmucin mast cells appeared to respond normally 
to antigen stimulation, and also to Tim4-mediated co-stimulation 
(Figure 4D). Using different batches of BMMCs over the course 
of multiple experiments, we were not able to consistently observe 
any major difference between WT and Tim-1Δmucin BMMCs. We did 
observe some variation in the amount of IL-6 produced by differ-
ent batches of BMMCs, but this appeared to be largely due to the 
relative maturation status of the cells (Figure 4E–H). These results 
indicated that the mucin domain of Tim-1 is not required for normal 
mast cell responses and also that Tim-4-mediated mast cell activa-
tion does not appear to involve the mucin domain of Tim-1, but 
rather its IgV domain.
Tim-1 enhances Ag-activated phosphorylation of ribosomal 
protein S6
Next, we assessed the potential signaling pathways utilized by 
Tim1-Tim4 interaction downstream of FcεRI signaling to upreg-
ulate mast cell cytokine production. Using a Nur77GFP reporter 
mouse, we previously showed that unlike the related family member 
Tim-3, engagement of Tim-1 did not enhance FcεRI signal inten-
sity, thereby showing that Tim-1 cross-linking does not augment 
antigen receptor-proximal signaling18. We moved on to explore sig-
naling pathways both proximal and distal to the FcεRI complex, 
for any effects of Tim-1. Thus, the Zap70-related kinase Syk is an 
FcεRIγ-associated activator integral to activation of LAT, SLP76, 
PLC-γ and other adaptor molecules essential for signal transduc-
tion downstream of FcεRI22. Phosphorylation of Syk was not fur-
ther increased by Tim-4 (Figure 5A). Similarly, we observed robust 
phosphorylation of ERK and Akt upon IgE/Ag-induced activation 
that was not affected by Tim-1 engagement (Figure 5B and data not 
shown). These results demonstrate that MEK/ERK and PI3K/Akt 
pathways are not involved in enhancement of Ag-mediated mast 
cell function by Tim-1, even though we observed that phosphoryla-
tion of Tim-1 cytoplasmic tail by TCR activation led to recruitment 
of p85 subunit of PI3K8. Nevertheless, we did detect a significant 
increase in phosphorylation of ribosomal protein S6, an impor-
tant target of the PI3K/mTOR pathway regulating cell growth, 
survival, metabolism, and protein synthesis in mast cells23. Mast 
cells exhibited robust phosphorylation of S6 (~80% of BMMCs) 
one hour post-Ag stimulation, which did not increase further with 
Tim-4 addition. However, Tim-4 treatment was able to maintain 
a significant percentage of pS6-positive BMMCs for as long as 
four hours, even as the Ag-triggered signal returned to basal levels 
(Figure 5C). Overall, these results support a positive role of 
Tim-1 activation by Tim-4 to sustain mTOR-dependent mast cell 
metabolism and protein synthesis, leading to enhanced cytokine 
production.
Discussion
Mast cells constitutively express high levels of cell-surface 
Tim-1, a molecule with co-stimulatory effects on many immune 
cell types, but with unclear mechanisms of action. Here we dem-
onstrate that Tim-1 is a positive regulator of mast cell activation 
and cytokine production. Similar to our findings on the effects of 
Tim-3 on mast cells18, ectopic expression of Tim-1 expression was 
sufficient to promote IgE/Ag-mediated NF-κB and NF-AT/AP1 
transcriptional activation (at least in MC/9 cells), without addi-
tional cross-linking antibodies or exogenous ligands. Tim-4 is a 
ligand for Tim-1, but the lack of Tim-4 expression on mast cells 
makes it an unlikely explanation for this particular role of Tim1 
in mast cells. Tim-1 can also bind PS on apoptotic cells24 or 
PS transiently exposed on degranulating mast cells, either of 
which could potentially contribute to enhance Tim-1 signal-
ing, although whether PS binding to Tim-1 can lead to mast cell 
activation is still unknown. Tim-1 has also been reported to bind 
LMIR5/CD300b, an activating receptor expressed on myeloid 
cells25. Stimulation with Tim1-Fc was able to induce LMIR5- 
mediated ERK activation in mast cells, suggesting that LMIR5 is 
an endogenous ligand of Tim-1, driving the enhancement of tran-
scriptional response. Finally, Tim-1 may homodimerize through its 
glycosylated mucin-like domain, leading to downstream signaling 
and function. We showed that Tim-1 co-stimulation is dependent 
on the tyrosine phosphorylation motif in its cytoplasmic tail, as 
mutation of tyrosine 276 rendered Tim-1 unable to mediate co- 
stimulation. The Src kinase Fyn has been shown to phosphorylate 
Tim-1 in a B cell line26. We showed that the Tim-1 cytoplasmic 
tail is phosphorylated upon TCR stimulation in an Lck-dependent 
manner and can recruit p85 binding8. Therefore, Src family kinases 
like Lyn, Fyn or Hck are potential facilitators of Tim-1 phosphor-
ylation upon IgE/Ag activation in mast cells.
Another aim of this study was to determine how Tim-1 cross-linking 
by antibodies or ligands could modulate mast cell activation. Unlike 
in T cells or in vivo experiments, mast cells did not respond to Tim-1 
antibody treatment, as none of the antibodies tested elicited a 
change in mast cell degranulation or cytokine production. On the 
other hand, Tim-4 treatment consistently enhanced IgE/Ag-mediated 
cytokine production but not degranulation, which may be a time- 
and/or signal intensity-dependent effect. Tim-4 was reported to 
have bimodal effects, either enhancing or inhibiting T cell prolifera-
tion, depending on anti-CD3/CD28 concentrations10. This bimodal 
regulation was later reported to inhibit activation of naïve T cells, 
which do not express Tim-1, and to enhance activation of effec-
tor T cells, suggesting that Tim-4 binds to an unknown ligand 
expressed preferentially on naïve T cells27. In addition, Tim-4 can 
bind to naïve T cells that do not express Tim-1 and inhibit Th17 
differentiation28. This effect was shown to be independent of Tim-1 
activity, since addition of Tim-1 blocking antibody, presumably to 
block the Tim1:Tim4 interaction, could not rescue Tim4-mediated 
inhibition28. In contrast to such ligand-dependent effects observed 
on T cells, Tim-4 co-stimulates IgE/Ag-mediated mast cell activa-
tion by cross-linking Tim-1. Using low and high valency antigens 
to engage the positive and negative signaling pathways of FcεRI, 
respectively, we showed that Tim-4 could enhance mast cell cytokine 
production in both settings. Specifically, Tim-4 co-stimulated 
cytokine release in a dose-dependent manner, under both high and 
low valency antigen stimulation. These results imply that Tim-4 
contributes to FcεRI signaling intensity and/or duration, and may 
potentially override negative feedback signals linked primarily to 
Lyn-mediated phosphatase activation. Together with findings that 
Tim-4 alone does not induce cytokine production in mast cells, our 
results demonstrate that Tim-1 signaling interfaces with common 
effector molecules downstream of FcεRI signaling, rather than 
acting through a parallel pathway, to enhance mast cell functions.
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Figure 5. Tim-1 ligation by Tim4-Fc enhances mast cell cytokine production by sustaining ribosomal protein S6 phosphorylation upon 
IgE/Ag activation. BL/6 BMMCs were sensitized overnight with IgE and stimulated with DNP32-HSA in the presence of isotype control or Tim4-Fc 
for the indicated time. Syk phosphorylation (Y519/520) (A), pErk (T202/Y204) (B), and pS6 (S235/236) (C) were analyzed by phospho-flow 
cytometry. Results are average of two independent experiments (A–B) or three independent experiments (C). *p<0.05, ***p<0.0005.
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To determine whether Tim-1 plays a positive or negative regulatory 
role in mast cells, we first attempted siRNA-mediated knockdown 
of Tim-1 protein in BMMCs but were unsuccessful in obtaining 
efficient reduction of Tim-1 expression. Furthermore, two sepa-
rate strains of Tim-1-deficient mice showed relatively unaltered 
IgE production and AHR development in an OVA-induced mouse 
model of asthma, although one study did note higher type 2 and 
Th17 cytokine production in Tim-1 knockout (KO) mice26,29. On the 
other hand, the importance of the Tim-1 mucin domain has been 
demonstrated in T cell activation, differentiation, trafficking, and 
effector function in autoimmunity and airway inflammation28,30. 
The mucin domain of Tim-1 is also essential for homeostasis and 
function of regulatory B cells14,15,21. Thus, we examined whether 
the Tim-1 mucin domain regulates mast cell activity, particularly 
in the context of Tim-4 treatment. Contrary to the effects seen in 
B and T cells, the mucin domain was dispensable for the effects 
of Tim-1 in mast cells, as degranulation and cytokine release were 
intact in the absence of the mucin domain. It is worth noting that 
Tim-1Δmucin BMMCs were actually able to secrete more cytokine 
than WT BMMCs in some instances. However, this was not a 
consistent finding. While our study focused on bone marrow-
derived mast cells, absence of the Tim-1 mucin domain may none-
theless affect the differentiation and/or function of other mast 
cell types in their respective tissue microenvironments in vivo. 
Tim1-Tim4 interactions are thought to occur mostly through their 
respective IgV domains, although there is evidence that Tim-4 may 
also bind to the Tim-1 mucin domain10. We showed that Tim-4 
mediated co-stimulation of mast cell function occurred independ-
ent of the Tim-1 mucin domain. It remains to be determined, in the 
absence of the Tim-1 mucin domain, whether Tim-4 has 
other unknown ligands on mast cells that can mediate this 
enhancement.
We also examined the signaling pathways upstream of enhanced 
transcriptional activation and cytokine production by Tim-1 and 
Ag co-stimulation in mast cells. Phosphorylation of Syk was not 
altered by Tim-4 treatment at the time points we examined. This 
is consistent with our finding that the Tim1-Tim4 interaction did 
not alter Ag-stimulated FcεRI signaling intensity, using mast cells 
from a Nur77GFP mouse model18. Syk is phosphorylated on multiple 
tyrosines by either auto-phosphorylation or trans-phosphorylation 
by Lyn, resulting in enhancement or inhibition, respectively, of 
Ag-mediated FcεRI signaling31–33. Since we only examined tyro-
sines 519 and 520 in the Syk activation loop, which are sites of 
Syk auto-phosphorylation, it is possible that other tyrosine phos-
phorylation sites of phosphorylation may be affected by Tim-1. One 
particular site of interest is tyrosine 346 in the linker region, which 
is important for PLC-γ1 binding and phosphorylation34. Aside from 
positive signaling pathways, the relevant negative signaling path-
ways should be investigated for potential down-regulation by Tim-
1 engagement. In particular, Src homology-2-containing signaling 
protein (SHIP), which has been implicated in regulation of IgE/ 
Ag-induced IL-6 production through inhibition of NF-κB 
activity, both of which are enhanced by Tim-1 cross-linking in our 
study35.
In a previous study, Tim-4 was shown to enhance phospho-
rylation of Erk and Akt in CD4 T cells9. These effects were not 
observed in a previous study on mast cells, with either BMMC’s 
or peritoneal mast cells (PMCs)16. Similarly, we did not observe 
effects of soluble Tim-4 on these signaling pathways, in conjunc-
tion with Ag-mediated FcεRI aggregation. It is possible that Tim-4 
signals are cell-type specific or that mast cells require more 
robust aggregation of Tim-1 at the time of antigen stimulation 
to induce substantial effects. While phosphorylation of Akt was 
not detectably affected, phosphorylation of ribosomal protein S6 
was significantly enhanced upon Tim-4 treatment, an effect that 
correlated with enhanced cytokine production. Ribosomal pro-
tein S6 is a downstream effector of PI3K/mTOR signaling, and 
as such is essential for mast cell survival, proliferation, metabo-
lism and protein synthesis. MALT1 and BCL10, members of the 
Carma1-MALT1-Bcl10 (CBM) complex, are essential regulators 
of FcεRI-induced mast cell activation by selectively up-regulating 
NF-κB-dependent cytokine production without affecting degran-
ulation and leukotriene synthesis36. We previously identified a 
Carma1-MALT1-dependent activation of mTOR signaling after 
TCR engagement, leading to phosphorylation of S6 and another 
mTOR substrate 4E-BP137. Thus, Tim-1 may preferentially engage 
the MALT1-Bcl10 pathway to modulate mTOR signaling and 
NF-κB responses without affecting FcεRI-proximal signaling. 
Consequently, further studies are needed to address whether 
Tim1-Tim4 interaction promotes mast cell metabolic responses 
and protein synthesis as well as whether the specific Tim-1 targets 
in this pathway leading to effector functions.
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have a co-stimulatory function for NF-kB and NFAT/AP1 transcription and cytokine production. 
A few points would be helpful to address in the final version of the manuscript.
Prior work has shown that Tim-1 recognizes phosphatidylserine on apoptotic cells and that the
mucin domain is important for this binding. Since the data presented here show that
annexin-binding (which detects PS) is upregulated as a function of mast cell degranulation, the
Tim-1 mucin domain might mediate homotypic interactions between recently degranulated cells.  Is
there evidence that this occurs (microscopy images or flow-based measures?) If this is a
mechanism to cluster Tim1 for activation, it will be in a “synapse”-like setting and would support a
post-degranulation, delayed co-stimulatory signal. As mentioned below, Tim-4 mediated activation 
 is probably in a synapse setting too, so there seems like a missed opportunity here.in vivo
 
This study relies a lot on exogenous agents (Tim4-Fc, antibodies) to make conclusions about the
role of Tim-1 signaling. This is fine as an experimental approach, but can confound the conclusions
reached about the role of the mucin domain. In other words, if one bypasses the mucin domain by
activating with Tim4-Fc, it does not necessarily mean that ligations mediated via the mucin domain
does not mediate signaling in another setting. I find, in general, that the emphasis on this result is
overstated/over-discussed as a physiological relevant finding. It provides more insight on the
structural features of Tim-1, which can apparently be activated by crosslinking (ie antibodies) or  by
binding to another Tim (Tim4) presented on another cell… and possibly when PS, presented on
another mast cell or an apoptotic cell in the inflammatory microenvironment, clusters Tim-1 via the
mucin domain.
In keeping with this, I think the discussion could be shortened and simplified.  For example, this
text could be omitted or reworded:
“Thus, we examined whether the Tim-1 mucin domain regulates mast cell activity, particularly in
the context of Tim-4 treatment. Contrary to the effects seen in B and T cells, the Tim-1 mucin
domain is dispensable for mast cell activity, as mast cell degranulation and cytokine release
remain intact in the absence of the mucin domain. It is worth noting that Tim-1 [] mucin BMMCs
were actually able to secrete more cytokine than WT BMMCs in some instances. However, after
testing six different batches of WT and Tim-1mucin BMMCs, it appeared that any differences
observed were due to the maturation status of BMMCs and their Fc[epsilon]RI surface expression,
rather than any direct effect of deletion of the Tim-1 mucin domain.”
 
This group has opted to use SPE-7 (anti-DNP) IgE to prime the BMMC.  Since this is a cytokinergic
IgE, it could be good to confirm that the essential findings of co-stimulation also occur when using
 a non-cytokinergic (anti-DNP) IgE …perhaps the Liu IgE.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Author Response (  and  ) 30 Jun 2016Member of the F1000 Faculty F1000Research Advisory Board Member
, Department of Immunology, University of Pittsburgh, USALarry Kane
Prior work has shown that Tim-1 recognizes phosphatidylserine on apoptotic cells and that
the mucin domain is important for this binding. Since the data presented here show that
annexin-binding (which detects PS) is upregulated as a function of mast cell degranulation,
the Tim-1 mucin domain might mediate homotypic interactions between recently
Page 14 of 18
F1000Research 2016, 5:251 Last updated: 11 JUL 2016
F1000Research
1.  
2.  
3.  
4.  
the Tim-1 mucin domain might mediate homotypic interactions between recently
degranulated cells.  Is there evidence that this occurs (microscopy images or flow-based
measures?) If this is a mechanism to cluster Tim1 for activation, it will be in a “synapse”-like
setting and would support a post-degranulation, delayed co-stimulatory signal. As
mentioned below, Tim-4 mediated activation is probably in a synapse setting too, so there
seems like a missed opportunity here.
The reviewer raises an interesting point regarding the regulation of Tim-1 by PS on
degranulating mast cells (although to our knowledge, the Tim1:PS interaction mainly
occurs through the Tim-3 IgV domain). We have not yet been able to image Tim-1
during mast cell activation, but feel that this would be an interesting topic for future
exploration.
 
This study relies a lot on exogenous agents (Tim4-Fc, antibodies) to make conclusions
about the role of Tim-1 signaling. This is fine as an experimental approach, but can
confound the conclusions reached about the role of the mucin domain. In other words, if one
bypasses the mucin domain by activating with Tim4-Fc, it does not necessarily mean that
ligations mediated via the mucin domain does not mediate signaling in another setting. I
find, in general, that the emphasis on this result is overstated/over-discussed as a
physiological relevant finding. It provides more insight on the structural features of Tim-1,
which can apparently be activated by crosslinking (ie antibodies) or  by binding to another
Tim (Tim4) presented on another cell… and possibly when PS, presented on another mast
cell or an apoptotic cell in the inflammatory microenvironment, clusters Tim-1 via the mucin
domain.
This is a fair point.We have modified the discussion of these results in line with this
comment and the one below.
In keeping with this, I think the discussion could be shortened and simplified.  For example,
this text could be omitted or reworded:
“Thus, we examined whether the Tim-1 mucin domain regulates mast cell activity,
particularly in the context of Tim-4 treatment. Contrary to the effects seen in B and T cells,
the Tim-1 mucin domain is dispensable for mast cell activity, as mast cell degranulation and
cytokine release remain intact in the absence of the mucin domain. It is worth noting that
Tim-1 d.mucin BMMCs were actually able to secrete more cytokine than WT BMMCs in
some instances. However, after testing six different batches of WT and Tim-1 d.mucin
BMMCs, it appeared that any differences observed were due to the maturation status of
BMMCs and their Fc[epsilon]RI surface expression, rather than any direct effect of deletion
of the Tim-1 mucin domain.”
This is a good suggestion – we have now edited the Discussion, to make it more
readable, and as a result it has been shortened by about one page.
 
This group has opted to use SPE-7 (anti-DNP) IgE to prime the BMMC.  Since this is a
cytokinergic IgE, it could be good to confirm that the essential findings of co-stimulation also
occur when using  a non-cytokinergic (anti-DNP) IgE …perhaps the Liu IgE.
We have only used the commercially available, and widely employed,SPE-7 IgE in
our studies. We agree that branching out to other IgE’s would be an interesting
avenue for future follow-up exploration.
 No competing interests were disclosed.Competing Interests:
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 15 March 2016Referee Report
doi:10.5256/f1000research.8748.r12697
 Avery August
Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA
There are a few issues that the authors should address as they refine the presentation of this work as
detailed below:
The authors should refer to the data in Figure 1A, the characterization of the TIM-4-Fc reagent and
expression of TIM-1 on the surface of these mast cells.
 
Since IgE alone has been shown to affect mast cell survival, does TIM-4/TIM-1 affect the mast cell
response to IgE alone?
 
In figure 1E, the graph looks as if there is production of IL-6 in the absence of IgE (third bar from
the left). Is this correct?
 
The location of the flag tag on TIM-1 should be described by the authors.
 
Do the antibodies against TIM-1 affect the ability of TIM-4 to enhance cytokine production?
 
The reference to a small although statistically insignificant increase in IL6 when 4G8 was used is
not appropriate to say, since the change is not significant, and not any larger than other changes
that are not remarked upon by the authors. This statement should be modified.
 
In experiments where TIM-1 is overexpressed in the MC/9 cell line, what is the ligand for the
transfected TIM-1?
 
Is calcium signaling affected by TIM-4/Tim-1 interaction? Is activation of Btk affected given the
potential role of PI3K downstream of TIM-1?
 
The statement in the 6  line of the discussion starting with “Tim-1 expression alone could promote
IgE/Ag-mediated NF- B and NF-AT/AP1 transcriptional activation…” should be qualified that this isk
in MC/9 cells, which may not behave like primary mast cells.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
Author Response (  and  ) 30 Jun 2016Member of the F1000 Faculty F1000Research Advisory Board Member
, Department of Immunology, University of Pittsburgh, USALarry Kane
The authors should refer to the data in Figure 1A, the characterization of the TIM-4-Fc
reagent and expression of TIM-1 on the surface of these mast cells.
This is now added to the Results, with an extra description of the Tim4-Fc in the
th
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This is now added to the Results, with an extra description of the Tim4-Fc in the
methods
 
Since IgE alone has been shown to affect mast cell survival, does TIM-4/TIM-1 affect the
mast cell response to IgE alone?
We did not test the IgE+Tim4-Fc condition ourselves but a previous paper from Galli
and colleagues (ref. 16 in the manuscript) showed that IgE + rmTim-4 did not trigger
degranulation, cytokine production, or prevent mast cell apoptosis from IL-3
withdrawal.
 
In figure 1E, the graph looks as if there is production of IL-6 in the absence of IgE (third bar
from the left). Is this correct?
That condition actually contains both IgE and the indicated antigen; the bar to the left
of it represents cells receiving only IgE and nothing else.
 
The location of the flag tag on TIM-1 should be described by the authors.
The tag is at the N-terminus. This is now stated explicitly in the Results section.
 
Do the antibodies against TIM-1 affect the ability of TIM-4 to enhance cytokine production?
We did not perform any blocking experiments with the Tim-1 antibodies in the
presence of Tim-4 fusion protein, but this would be an interesting future experiment.
 
The reference to a small although statistically insignificant increase in IL6 when 4G8 was
used is not appropriate to say, since the change is not significant, and not any larger than
other changes that are not remarked upon by the authors. This statement should be
modified.
This is a good point. We have now modified the sentence in question which refers to
Fig. 2F in the results section to make it more accurately and clearly reflect the data.
 
In experiments where TIM-1 is overexpressed in the MC/9 cell line, what is the ligand for the
transfected TIM-1?
In our previous publications, we observed what appears to be constitutive activity of
the transfected Tim-1 after transient transfection. We have generally interpreted this
to indicate that ectopically expressed Tim-1 is oligomerizing in the absence of ligand,
since it is expressed at higher than normal levels on at least a subset of the
transfected cells.
 
Is calcium signaling affected by TIM-4/Tim-1 interaction? Is activation of Btk affected given
the potential role of PI3K downstream of TIM-1?
Given the data we have presented in the manuscript, it is indeed logical that a Tec
family kinase like Btk may be a proximal target for Tim-1. We have started to address
this by probing the effects of Tim-1 on PLC-g1 phosphorylation, but have not been
able to observe a robust effect. However, given the limited personnel available to
work currently on this project, we thought that it was important to share the results
that we have obtained, which may be of interest to others studying the function of
Tim-1.
The statement in the 6  line of the discussion starting with “Tim-1 expression alone could
promote IgE/Ag-mediated NF- B and NF-AT/AP1 transcriptional activation…” should bek
qualified that this is in MC/9 cells, which may not behave like primary mast cells.
This is a good point. We have now clarified in the Discussion that this was in MC/9
th
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This is a good point. We have now clarified in the Discussion that this was in MC/9
cells.
 No competing interests were disclosed.Competing Interests:
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